Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary systemic amyloidosis--a diagnostic primer.

M A Gertz1, R A Kyle

  • 1Dysproteinemia Clinic, Mayo Clinic, Rochester, MN 55905.

Mayo Clinic Proceedings
|December 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024
Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023
Same author

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Blood cancer journal·2021
Same author

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2021
Same author

Systemic amyloidosis from A (AA) to T (ATTR): a review.

Journal of internal medicine·2020
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Primary systemic amyloidosis (AL) is a rare disease with varied symptoms. Early detection via serum and urine screening improves outcomes, with survival depending heavily on organ involvement, particularly heart failure.

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Primary systemic amyloidosis, also known as immunoglobulin light chain-derived (AL) amyloidosis, is an uncommon plasma cell dyscrasia.
  • It is characterized by the deposition of misfolded immunoglobulin light chains in various organs, leading to organ dysfunction.

Observation:

  • This study analyzed 153 patients diagnosed with AL amyloidosis.
  • Clinical manifestations were highly varied, impacting initial diagnosis and prognosis.

Findings:

  • The median survival for patients with AL amyloidosis was 20.4 months, with a 5-year survival rate of 19.6%.
  • Overt congestive heart failure significantly worsened prognosis, with a median survival of 7.7 months.
  • Patients with amyloid neuropathy without cardiac or renal involvement had the best outcomes, with a median survival of 39.7 months.

Related Experiment Videos

Implications:

  • Serum protein electrophoresis and immunoelectrophoresis are crucial diagnostic tools, detecting monoclonal proteins in nearly two-thirds of patients.
  • Combined serum and urine screening increases monoclonal protein detection to 86%, facilitating earlier diagnosis and treatment.
  • Early detection and prompt treatment are vital for improving survival rates in AL amyloidosis.